The British government has indefinitely banned the use of puberty blockers for children with gender dysphoria. The decision, announced on Wednesday, follows findings by independent experts that the medication poses unacceptable safety risks. The ban, which will be revisited in 2027, halts a widely used approach to medical gender transitions for young people in the UK.
This decision aligns with the National Health Service’s (NHS) earlier move to stop prescribing puberty blockers at gender identity clinics due to insufficient evidence of their benefits and risks.
The ban prevents prescribing medications designed to suppress or pause puberty in children with gender dysphoria, giving them more time to consider other options, including potential gender reassignment procedures. However, it does not affect:
The measure applies across the United Kingdom following consultations with devolved governments in Scotland, Wales, and Northern Ireland.
Health Secretary Wes Streeting stated that a clinical trial would be initiated in 2024 to evaluate the drugs’ use comprehensively. “We need to act with caution and care when it comes to this vulnerable group of young people and follow the expert advice,” he said.
Justice Beverley Lang, who upheld an emergency ban earlier this year, cited a review by the NHS that highlighted substantial risks and narrow benefits of the treatment. She emphasized the lack of strong evidence in this area, describing gender care as embroiled in “stormy social discourse.”
Trans rights advocates, including the group TransActual, have criticized the decision. Keyne Walker, TransActual’s strategy director, called the move discriminatory, claiming, “Evidence of the harm of the temporary ban continues to emerge, and will grow now that it has been made permanent.”
The British Medical Association has also questioned the NHS review, voting to conduct an independent, evidence-based evaluation of the findings.
While the government’s stance reflects caution, critics argue the ban disproportionately impacts transgender youth and limits their access to care. As clinical trials begin in 2024, the debate over puberty blockers is expected to continue, highlighting the need for robust, evidence-based policies in this sensitive area.
